Regeneron Pharmaceuticals has received approval from the U.S. Food and Drug Administration (FDA) for its number one selling eye injection EYLEA for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). In 2014, the FDA granted EYLEA Breakthrough Therapy designation and Priority Review for the treatment of diabetic retinopathy in patients with DME. “Diabetic retinopathy coupled with DME is a serious complication of diabetes that can threaten the vision of m...